- Home
- SOPH vs CERS Comparison
SOPH vs CERS Comparison
Compare SOPH & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- CERS
- Stock Information
- Founded
- SOPH 2011
- CERS 1991
- Country
- SOPH Switzerland
- CERS United States
- Employees
- SOPH N/A
- CERS N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- CERS EDP Services
- Sector
- SOPH Health Care
- CERS Technology
- Exchange
- SOPH Nasdaq
- CERS Nasdaq
- Market Cap
- SOPH 231.8M
- CERS 276.0M
- IPO Year
- SOPH 2021
- CERS 1997
- Fundamental
- Price
- SOPH $4.52
- CERS $1.45
- Analyst Decision
- SOPH
- CERS Buy
- Analyst Count
- SOPH 0
- CERS 1
- Target Price
- SOPH N/A
- CERS $4.00
- AVG Volume (30 Days)
- SOPH 144.5K
- CERS 1.2M
- Earning Date
- SOPH 11-04-2025
- CERS 11-06-2025
- Dividend Yield
- SOPH N/A
- CERS N/A
- EPS Growth
- SOPH N/A
- CERS N/A
- EPS
- SOPH N/A
- CERS N/A
- Revenue
- SOPH $73,297,000.00
- CERS $192,510,000.00
- Revenue This Year
- SOPH $16.60
- CERS $19.07
- Revenue Next Year
- SOPH $19.09
- CERS $12.03
- P/E Ratio
- SOPH N/A
- CERS N/A
- Revenue Growth
- SOPH 13.66
- CERS 13.25
- 52 Week Low
- SOPH $2.58
- CERS $1.12
- 52 Week High
- SOPH $5.30
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- SOPH 53.20
- CERS 46.04
- Support Level
- SOPH $4.01
- CERS $1.48
- Resistance Level
- SOPH $5.11
- CERS $1.54
- Average True Range (ATR)
- SOPH 0.39
- CERS 0.08
- MACD
- SOPH 0.02
- CERS -0.02
- Stochastic Oscillator
- SOPH 49.68
- CERS 19.23
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.